Overview

Study In Patients With Kidney Cancer Treated With Sutent

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
Objective of this study is to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib.
Details
Lead Sponsor:
Pfizer
Treatments:
Sunitinib